Fig. 2: FADS promotes tumor growth and restrains T cell-mediated antitumor immunity. | Nature Communications

Fig. 2: FADS promotes tumor growth and restrains T cell-mediated antitumor immunity.

From: FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma

Fig. 2

a Comparison of FLAD1 expression between tumors and non-tumor liver samples in 18 HCC datasets from the HCCDB database. b FLAD1 mRNA levels in paired tumors (T) and adjacent livers (N) from Cohort-A (n = 30 pairs). c FADS protein levels in paired tumors (T) and adjacent livers (N) from Cohort-A (n = 6 pairs). Data from 3 independent experiments with similar results. d Representative images and quantification of FADS staining in paired tumors and liver samples from Cohort-B (n = 42 pairs). Quantification is based on H-scores. e Kaplan-Meier overall survival curves of TCGA-LIHC and OEP000321 cohorts, stratified by FLAD1 expression with optimal cutoffs defined by the surv_cutpoint function. f Tumor FLAD1 expression in patients with partial response or progressive disease to immunotherapy (Fudan Cohort, n = 17). g Proportions of FLAD1+ tumor cells in patients with partial response or stable disease (Immunotherapy Cohort, n = 8). h Subcutaneous tumors were established in C57BL/6 mice with Hepa1-6 cells (Ctrl or shFlad1, n = 5 per group). Tumor volumes were measured at the indicated timepoints. Tumors were photographed and weighed at day 21. i, j Orthotopic tumors were established in C57BL/6 mice with Hepa1-6 cells (Ctrl or shFlad1, n = 6 per group). Livers were photographed and weighed at day 21 (i). Bioluminescence imaging was used to visualize tumors at days 14 and 21 (j). k Subcutaneous tumors in Rag1-/- mice with Hepa1-6 cells (Ctrl or shFlad1, n = 6 per group). Tumor volumes were measured at the indicated timepoints. Tumors were photographed and weighed at day 21. l, m Orthotopic tumors in Rag1-/- mice with Hepa1-6 cells (Ctrl or shFlad1, n = 5 per group). Livers were photographed and weighed at day 21 (l). Bioluminescence imaging was used to visualize tumors at days 14 and 21 (m). Data are presented as mean ± SD (f–h, i, k, l) or median with interquartile ranges (d). P-values were calculated using two-way ANOVA with Tukey’s test (h, k), unpaired two-sided Student’s t test (f, k, l), two-sided Wilcoxon signed-rank test (d), two-sided Wilcoxon rank-sum test (g–i), and log-rank test (e). Source data are provided as a Source Data file.

Back to article page